Ulevostinag
Ulevostinag (MK-1454) is a potent cyclic dinucleotide agonist stimulator of interferon genes (STING). Ulevostinag (MK-1454) acts in the intra-tumoral route by targeting the stimulator of interferon genes (STING) protein. Ulevostinag (MK-1454) can be used for immuno-tumor cancer disease research.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 2082743-96-0
- 分子式: C20H22F2N10O9P2S2
- 分子量:710.52
-
保管条件:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
生物活性
Ulevostinag (MK-1454) (4 μg for intratumorally on day 0, 3 and 7) results in complete tumor regression and enhances the efficacy of anti-PD1 therapy in MC38 and B16F10 tumor mice model[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:MC38 colon adenocarcinoma tumor-bearing mice[1]
-
Dosage:5 μg, 20 μg
-
Administration:intratumorally
-
Result:Regressed the injected (right) tumors and was detected in injected and noninjected tumors as well as plasma when dosed at 20 μg.
Elevated IFN-β and proinflammatory cytokines IL-6 and TNF-α in injected tumors.
-
Animal Model:MC38 and B16F10 tumor mice model[1]
-
Dosage:4 μg
-
Administration:intratumorally
-
Result:Improved tumor growth inhibition with 7 CRs out of 10 mice over 28 days.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
化学情報
-
CAS 番号 2082743-96-0
-
性状 Solid
-
分子量 710.52
-
分子式 C20H22F2N10O9P2S2
-
Color White to off-white
-
SMILES
F[C@H]1[C@](O[P@](S)(OC[C@](O[C@](N2C3=NC=NC(N)=C3N=C2)([H])[C@H]4F)([H])[C@@]4([H])O5)=O)([H])[C@@](N6C(NC(N)=NC7=O)=C7N=C6)([H])O[C@]1([H])CO[P@]5(S)=O
-
別名
MK-1454
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
純度とドキュメンテーション
-
データシート (276 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. Zawit M, et al. Current status of intralesional agents in treatment of malignant melanoma. Ann Transl Med. 2021 Jun;9(12):1038. [Content Brief]
[2]. Gogoi H, et al. The Age of Cyclic Dinucleotide Vaccine Adjuvants. Vaccines (Basel). 2020 Aug 13;8(3):453. [Content Brief]
[3]. Chang W, et al. Discovery of MK-1454: A Potent Cyclic Dinucleotide Stimulator of Interferon Genes Agonist for the Treatment of Cancer. J Med Chem. 2022 Apr 14;65(7):5675-5689. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Ulevostinag 関連分類
HY-139586 関連分類
Powered by Bioz